L39. Fulminant ANCA vasculitis

MeSH terms

• Acute Kidney Injury / diagnosis*
• Acute Kidney Injury / drug therapy
• Acute Kidney Injury / etiology*
• Acute Kidney Injury / mortality
• Adrenal Cortex Hormones / therapeutic use
• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / complications*
• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / diagnosis*
• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy
• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / mortality
• Cause of Death
• Churg-Strauss Syndrome / complications
• Churg-Strauss Syndrome / diagnosis
• Churg-Strauss Syndrome / drug therapy
• Churg-Strauss Syndrome / mortality
• Cyclophosphamide / therapeutic use
• Drug Therapy, Combination
• Gastrointestinal Diseases / diagnosis*
• Gastrointestinal Diseases / drug therapy
• Gastrointestinal Diseases / etiology*
• Gastrointestinal Diseases / mortality
• Granulomatosis with Polyangiitis / complications
• Granulomatosis with Polyangiitis / diagnosis
• Granulomatosis with Polyangiitis / drug therapy
• Granulomatosis with Polyangiitis / mortality
• Heart Diseases / diagnosis
• Heart Diseases / drug therapy
• Heart Diseases / etiology
• Heart Diseases / mortality
• Hemorrhage / diagnosis*
• Hemorrhage / drug therapy
• Hemorrhage / etiology*
• Hemorrhage / mortality
• Humans
• Immunosuppressive Agents / therapeutic use
• Lung Diseases / diagnosis*
• Lung Diseases / drug therapy
• Lung Diseases / etiology*
• Lung Diseases / mortality
• Microscopic Polyangiitis / complications
• Microscopic Polyangiitis / diagnosis
• Microscopic Polyangiitis / drug therapy
• Microscopic Polyangiitis / mortality
• Neurologic Examination
• Pulmonary Alveoli*
• Survival Rate